Amod Sarnaik
Moffitt Cancer Center · H. Lee Moffitt Cancer Center and Research Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Amod Sarnaik as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:57 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05628883 · Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory MelanomaH. Lee Moffitt Cancer Center and Research Institute · completed · Metastatic Melanoma, Unresectable Melanoma, Acral Melanoma · principal investigator
- Early Ph1NCT02652455 · Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic MelanomaH. Lee Moffitt Cancer Center and Research Institute · completed · Melanoma (Skin), Skin Cancer · principal investigator
- N/ANCT01701674 · Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets PtsH. Lee Moffitt Cancer Center and Research Institute · completed · Metastatic Melanoma · principal investigator
- Ph2NCT01659151 · Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic MelanomaH. Lee Moffitt Cancer Center and Research Institute · completed · Metastatic Melanoma · principal investigator
- N/ANCT01005745 · Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic MelanomaH. Lee Moffitt Cancer Center and Research Institute · completed · Metastatic Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:57 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Co-Stimulation to Enhance Adoptive Cell Therapy for Metastatic MelanomaK23CA178083 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · fiscal years 2013 to 2017 · $75,778 awarded in 2017Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:57 UTC. The ranking covers the 200 most relevant of 17 PubMed records, and a shared surname and initials can bring in a namesake. All 17 on PubMed
- Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.J Clin Oncol · 2013459 citationsRCR 11.6
- Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial.Nat Med · 2021386 citationsRCR 17.3
- 332 citationsRCR 20.2
- Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma.Clin Cancer Res · 2011167 citationsRCR 3.5
- Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.J Immunother · 2012162 citationsRCR 3.5
- Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: a prospective, double-blind, randomized trial.Crit Care Med · 1994100 citationsRCR 3.8
- Dexamethasone for the prevention of postextubation airway obstruction: a prospective, randomized, double-blind, placebo-controlled trial.Crit Care Med · 199689 citationsRCR 4.3
- The unique clinical characteristics of melanoma diagnosed in children.Ann Surg Oncol · 201250 citationsRCR 1.6
- Indicators of postpyloric feeding tube placement in children.Crit Care Med · 200046 citationsRCR 2.2
- Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.Clin Cancer Res · 202242 citationsRCR 2.4